Construct anticancer drug-drug correlation network
Pages 771 - 775
Abstract
Network biology methods have been promising in linking diseases, genes, and drugs. In this study, we propose a novel computational method to construct drug-drug correlation networks, which consist of drug compounds as network graph nodes and correlated protein-drug profiles above a pre-determined threshold as network graph edges. This computational method is based on extensions of related work on identifying disease-specific proteins within protein-protein sub-networks, and mining protein-drug association profiles from biomedical literature. Our method provides a quantitative framework to compare how each drug compound from one therapeutic area is correlated with other drug compounds in other therapeutic areas, using a drug's protein-drug association profile mined from biomedical literature. We applied this method to the study of drug re-purposing and found that two breast cancer drugs "Mitomycin" and "Bleomycin" may be top drug candidates for treating pancreatic cancers.
References
[1]
Imming, P., Sinning, C., and Meyer, A., Drugs, their targets and the nature and number of drug targets. Nature reviews Drug discovery, 2006. 5(10): p. 821--34.
[2]
Yildirim, M. A., et al., Drug-target network. Nature biotechnology, 2007. 25(10): p. 1119--26.
[3]
Goh, K. I., et al., The human disease network. Proceedings of the National Academy of Sciences of the United States of America, 2007. 104(21): p. 8685--8690.
[4]
Hopkins, A. L., Network pharmacology. Nature biotechnology, 2007. 25(10): p. 1110--1.
[5]
O'Connor, K. A. and Roth, B. L., Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nature reviews Drug discovery, 2005. 4(12): p. 1005--14.
[6]
American Cancer Society, Cancer Facts & Figures 2008, Atlanta: American Cancer Society; 2008.
[7]
Laheru, D. and Jaffee, E. M., Immunotherapy for pancreatic cancer - science driving clinical progress. Nature reviews Cancer, 2005. 5(6): p. 459--67.
[8]
Li, J., Zhu, X., and Chen, J. Y. Mining Disease-Specific Molecular Association Profiles from Biomedical Literature: A Case Study. in ACM Symposium on Applied Computing 2008. 2008. Fortaleza, Brazil.
[9]
Chen, J. Y., Shen, C., and Sivachenko, A. Y., Mining Alzheimer disease relevant proteins from integrated protein interactome data. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2006: p. 367--378.
[10]
Hamosh, A., et al., Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic acids research, 2005. 33(Database issue): p. D514--517.
[11]
HAPPI: Human Annotated and Predicted Protein Interaction. http://discern.uits.iu.edu:8340/HAPPI/index.html.
[12]
Li, J., et al. Learning Domain-Specific Knowledge from Context--THUIR at TREC2005 Genomics Track. in Proceedings of 14th Text Retrireval Conference (TREC2005). 2005. Gaithersburg, USA.
[13]
MeSH: Medical Subject Headings (acess 2007). http://www.nlm.nih.gov/mesh/.
[14]
Wu, C. H., et al., The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic acids research, 2006. 34(Database issue): p. D187--91.
[15]
Huan, T., et al., ProteoLens: a visual analytic tool for multi-scale database-driven biological network data mining. BMC Bioinformatics, 2008. 9(Suppl 9): p. S5.
[16]
2008 MEDLINE/PubMed Baseline Data. http://www.nlm.nih.gov/bsd/licensee/2008_stats/baseline_doc.htm l.
[17]
Mitomycin in Clinical Trials. http://clinicaltrials.gov/ct2/show/record/NCT00386399?term=Mit omycins&rank=11.
[18]
Bleomycin in ClinicalTrhials http://clinicaltrials.gov/ct2/show/record/NCT00027521?term=Bleomycin&rank=14.
Index Terms
- Construct anticancer drug-drug correlation network
Recommendations
Implications of trinodal inhibitions and drug repurposing in MAPK pathway: A putative remedy for breast cancer
AbstractBreast cancer has been one of the supreme causes of cancer-related deaths among women worldwide. To make the case even more compounded, due to innate or acquired causes, cancer cells often develop resistance against the available chemotherapy or ...
Graphical abstractDisplay Omitted
Highlights- A multitargeted breast cancer therapy simultaneously targets PDPK1, ERK1/2, and mTOR of the MAPK pathway with more efficacy than monotargeted ones.
- MP7 had the most superior binding affinities for all three target nodes, often more ...
Drug Repurposing: Targeting mTOR Inhibitors for Anticancer Activity
CSBio '17: Proceedings of the 8th International Conference on Computational Systems-Biology and BioinformaticsIn the search of safer and more effective drugs while reducing costs and increasing productivity of novel drug discovery, scientists are changing their focus to an approach known as drug repurposing. This involves finding a new therapeutic effect of an ...
Drug promiscuity: Exploring the polypharmacology potential of 1, 3, 6-trisubstituted 1, 4-diazepane-7-ones as an inhibitor of the ‘god father’ of immune checkpoint
Graphical abstractDisplay Omitted
Highlights- We used the similarities in the binding site of unsimilar proteins to repurpose an existing inhibitor.
AbstractHigh production cost, instability, low tumor penetration are some of the shortcomings that have characterized and undermined the use of antibodies as a target for Cytotoxic T-lymphocytes associated protein 4 (CTLA-4). Design and ...
Comments
Information & Contributors
Information
Published In
March 2009
2347 pages
Copyright © 2009 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
Sponsors
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 08 March 2009
Check for updates
Author Tags
Qualifiers
- Research-article
Conference
SAC09
Sponsor:
Acceptance Rates
Overall Acceptance Rate 1,650 of 6,669 submissions, 25%
Upcoming Conference
SAC '25
- Sponsor:
- sigapp
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 272Total Downloads
- Downloads (Last 12 months)1
- Downloads (Last 6 weeks)0
Reflects downloads up to 08 Mar 2025
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign in